Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across ...

Bristol Myers Squibb outperformed expectations in the second quarter, with boosted sales from key brands Eliquis, Opdivo, and ...

Bristol Myers Squibb reported impressive second-quarter results with stronger-than-anticipated sales from its key brands Eliquis, Opdivo, and Revlimid. Despite challenges from generic competitors, the ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Shares of Bristol-Myers Squibb (NYSE:BMY) popped 2.4% premarket on Thursday after the pharma giant beat Street forecasts with ...

(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

Blowout results from megacaps Microsoft and Meta catapulted U.S. stock futures up more than 1% on Thursday, while an ...

Bristol Myers Squibb (BMY) is gearing up for its earnings release this Thursday. Historically, the stock's one-day ...

My monthly update and commentary on the top dividend stock picks from Barron's Better Bets, July 2025 edition. Read the full ...

Novo Nordisk promoted Maziar Mike Doustdar to president and CEO, effective August 7. The Food and Drug Administration tapped newly appointed George Tidmarsh as acting Center for Biologics Evaluation ...